Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial

Hypertension

Volumn 59, Issue 5, 2012, Pages 926-933

  Alderman, Michael H ^a   Piller, Linda B ^b   Ford, Charles E ^b   Probstfield, Jeffrey L ^c   Oparil, Suzanne ^d   Cushman, William C ^e   Einhorn, Paula T ^f   Franklin, Stanley S ^g   Papademetriou, Vasilios ^h   Ong, Stephen T ⁱ   Eckfeldt, John H ^j   Furberg, Curt D ^k   Calhoun, David A ^d   Davis, Barry R ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d University of Alabama at Birmingham   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ Ong Medical Center   (United States)

^j UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^k WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Angiotensin converting enzyme inhibitor; Calcium channel blocker; Diuretic; Hyperkalemia; Hypertension; Hypokalemia

Indexed keywords

AMLODIPINE; CHLORTALIDONE; LISINOPRIL; POTASSIUM;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL PRACTICE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; STROKE;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD CHEMICAL ANALYSIS; CARDIOVASCULAR DISEASES; CHLORTHALIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; INCIDENCE; KAPLAN-MEIER ESTIMATE; LISINOPRIL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84860214375     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.180554     Document Type: Article

References (20)

1. Cohen HW, Madhavan S, Alderman MH. High and low serum potassium associated with cardiovascular events in diuretic-treated patients. J Hypertens. 2001;19:1315-1323. (Pubitemid 32595289)
2. Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol. 2006;17:S25-S29.
3. Freis ED. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med. 1995;122:223-226.
4. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program. Hypertension. 2000; 35:1025-1030. (Pubitemid 30327250)
5. Papademetriou V. Diuretics, hypokalemia, and cardiac arrhythmia: a 20-year controversy. J Clin Hypertens (Greenwich). 2006;8:86-92.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
7. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360. (Pubitemid 26128245)
8. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239-246.
9. Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, Farber M, Payne G, Probstfield J, Ward H, ALLHAT Research Group. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials. 2001;22:674-686. (Pubitemid 33153035)
10. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Regression. New York, NY: Springer-Verlag; 1997.
11. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354:2473-2483. (Pubitemid 43855050)
12. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239-241.
13. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease: part 2-short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838. (Pubitemid 20113741)
14. Bazzano LA, He J, Ogden LG, Loria C, Vupputuri S, Myers L, Whelton PK. Dietary potassium intake and risk of stroke in US men and women: National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Stroke. 2001;32:1473-1479. (Pubitemid 32631891)
15. Walsh CR, Larson MG, Leip EP, Vasan RS, Levy D. Serum potassium and risk of cardiovascular disease: the Framingham Heart Study. Arch Intern Med. 2002;162:1007-1012. (Pubitemid 34492529)
16. Fang J, Madhavan S, Cohen H, Alderman MH. Serum potassium and cardiovascular mortality. J Gen Intern Med. 2000;15:885-890. (Pubitemid 32011839)
17. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
18. Mann JFE, Yi Q, Sleight P, Dagenais GR, Gerstein HC, Lonn EM, Bosch J, Yusuf S. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE Study. Clin Nephrol. 2005;63:181-187. (Pubitemid 40372073)
19. Turnbull F, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535. (Pubitemid 37410190)
20. Aziz EF, Javed F, Korniyenko A, Pratap B, Cordova JP, Alviar CL, Herzog E. Mild hyperkalemia and low eGFR a tedious recipe for cardiac disaster in the elderly: an unusual reversible cause of syncope and heart block. Heart Int. 2011;6:e12.